Related Experiment Video
Updated: May 5, 2026
08:56
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
Published on: February 10, 2015
54.3K
Primary Biliary Cholangitis With Incomplete Response to Conventional Therapies But Had Complete Response to
Gi Eun Kim1, Mariam Imran1, Sherif Mostafa1
1Department of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar, hamad.qa.
Case Reports in Hepatology
|December 31, 2025
Summary
This case study shows baricitinib effectively normalized alkaline phosphatase levels in a primary biliary cholangitis patient unresponsive to other treatments. Baricitinib offers a new therapeutic option for managing this progressive liver disease.
Area of Science:
- Hepatology
- Immunology
- Pharmacology
Background:
- Primary biliary cholangitis (PBC) is a progressive autoimmune liver disease.
- Complications include liver cirrhosis and hepatocellular carcinoma.
- Treatment aims to delay disease progression and improve outcomes.
Purpose of the Study:
- To report a case of PBC with incomplete response to standard therapies.
- To evaluate the efficacy of baricitinib in a treatment-resistant PBC patient.
- To highlight baricitinib's potential in normalizing alkaline phosphatase levels.
Main Methods:
- A single-case study design.
- Patient with PBC received ursodeoxycholic acid, obeticholic acid, and fenofibrate.
- Treatment was switched to baricitinib due to incomplete response.
- Alkaline phosphatase levels were monitored as a key treatment response marker.
Main Results:
- The patient showed an incomplete response to ursodeoxycholic acid, obeticholic acid, and fenofibrate.
- Baricitinib treatment resulted in sustained normalization of alkaline phosphatase levels.
- This indicates a complete treatment response in terms of biochemical markers.
Conclusions:
- Baricitinib demonstrated significant efficacy in a PBC patient with inadequate response to existing therapies.
- Sustained normalization of alkaline phosphatase suggests baricitinib's potential as a treatment option for refractory PBC.
- Further research is warranted to confirm baricitinib's role in PBC management.
More Related Videos
Related Concept Videos
01:17Chronic Bowel Disorders: Introduction
900
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
900
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:29Chronic Pancreatitis II: Collaborative Care
563
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
563
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K